Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography

Patients will receive subcutaneous injections of PCSK9 inhibitors and oral administration of background LMT (including statins and/or cholesterol absorption inhibitors) for the first 12 months after randomization, with PCSK9 inhibitors administered every 2 weeks. After the first 12 months, patients will discontinue the PCSK9 inhibitors but continue background LMT for the remainder of the trial.

Patients will receive subcutaneous injections of placebo and oral administration of background LMT (including statins and/or cholesterol absorption inhibitors) for the first 12 months after randomization, with placebo administered every 2 weeks. After the first 12 months, patients will discontinue the placebo but continue background LMT for the remainder of the trial.